Aarti Industries Q2FY26: ₹2,250 Cr Revenue, ₹105 Cr PAT, 68% YoY Profit Jump — Is the Chemical King Getting Its Mojo Back or Just a Temporary Reaction?
1. At a Glance
Aarti Industries Ltd (NSE: AARTIIND), the ₹14,146 crore market cap specialty chemicals veteran, just dropped its Q2FY26 results, and for once, the periodic table didn’t disappoint. Revenue shot up to ₹2,250 crore, EBITDA clocked ₹292 crore, and PAT landed at ₹105 crore — a 68% YoY jump. Yes, the same Aarti that’s been stuck in chemical purgatory for two years finally remembered it’s supposed to make profits.
The stock, however, continues to play hide-and-seek with investors — currently lounging at ₹390 per share, down 25% in a year. At 52.6x P/E, this molecule ain’t cheap, but the street seems to think it might just be stabilizing after a long hangover from raw material inflation, global destocking, and the infamous “China Syndrome.”
Return ratios are still gasping — ROE at 6.03%, ROCE at 6.32%. Yet, with 29% quarterly revenue growth and new high-margin projects in the pipeline, Aarti might finally be ready to step out of the chemical coma.
So, is this just a temporary high or a sustainable reaction? Strap in — the beaker’s bubbling.
2. Introduction
Once upon a time, in the dusty lanes of Vapi and Jhagadia, a small group of chemical engineers decided to turn benzene into billions. The result? Aarti Industries — India’s answer to “how many things can you make from one molecule.”
From dyes to drugs, fertilizers to pharma intermediates, Aarti has mastered the art (pun intended) of extracting value out of every atom. Over the decades, it became a poster child for the Indian specialty chemicals boom — until global slowdowns and margin squeezes started turning its periodic table into a Sudoku puzzle.
The last two years have been tough. Exports got hit, energy costs went through the roof, and the Chinese dumped products like they were running a clearance sale. But Q2FY26 numbers show a whiff of recovery: revenue up 29% YoY, profit up 68%. Capex projects are nearing completion, energy costs are stabilizing, and its mega “Zone IV” site could be the next growth laboratory.
Still, the street’s reaction is cautious — after all, the company’s P/E is higher than its EBITDA margin. And in chemicals, that’s like wearing Gucci boots to a sulfuric acid plant — looks great till it burns through.
Will Aarti finally return to its old high-margins, or is this just another “lab trial” phase? Let’s find out.
3. Business Model – WTF Do They Even Do?
Think of Aarti Industries as India’s molecular McDonald’s — same raw materials, different menu. The company runs multiple production chains, all starting from a handful of basic chemicals like benzene, toluene, and sulphuric acid — and somehow ends up feeding industries as diverse as agrochemicals, pharmaceuticals, polymers, and dyes.
Key Value Chains:
Benzene Chain: The company’s crown jewel. Aarti is the world leader in Dichloro Benzenes (DCB) and top three globally in Nitro Chloro Benzenes (NCB). These feed into products for Bayer, BASF, and Huntsman.
Toluene Chain: Produces derivatives like toluidines and nitrotoluenes — critical for pharma and agro intermediates.
Sulphuric Acid Chain: Sounds boring, but this is the backbone of India’s industrial acid demand — Aarti makes everything from Oleum to Di-Methyl Sulphate.
Hydrogenation, Ethylation, Fluorination: The cool lab stuff — high-value niche products that separate the men from the mole ratios.
And yes, they’re building an entire ecosystem called “Zone IV” at Jhagadia — a 95-acre chemical Disneyland that will host future specialty products.
If you’re wondering what all this means — basically, if India needs to color something, clean something, protect crops, or make painkillers, chances are Aarti has supplied a molecule somewhere in the chain.
4. Financials Overview
Let’s break down the latest quarterly chemistry experiment.
Metric
Q2 FY26
Q2 FY25
Q1 FY26
YoY %
QoQ %
Revenue (₹ Cr)
2,250
1,749
2,100
28.6%
7.1%
EBITDA (₹ Cr)
292
218
291
34%
0.3%
PAT (₹ Cr)
105
62
84
69%
25%
EPS (₹)
2.92
1.74
2.33
68%
25%
Annualized EPS: ₹11.68 → P/E = 33.4x on annualized, versus reported 52.6x on TTM.
